Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sandoz s.p.a. - itraconazolo - itraconazolo

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sun pharmaceutical industries (europe) b.v. - perindopril - perindopril

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sandoz gmbh - itraconazolo - itraconazolo

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

servier (suisse) sa - atorvastatinum, perindoprilum, amlodipinum - compressa rivestita con film - atorvastatinum 10 mg ut atorvastatinum calcicum trihydricum 10.82 mg, perindoprilum argininum 5 mg corresp. perindoprilum 3.395 mg, amlodipinum 5 mg ut amlodipini besilas 6.935 mg, calcii carbonas, lactosum monohydricum 27.46 mg, cellulosum microcristallinum, carboxymethylamylum natricum corresp. natrium 0.25 - 0.38 mg, hydroxypropylcellulosum, maltodextrinum, magnesii stearas, pellicule: glycerolum, hypromellosum, macrogolum 6000, magnesii stearas, e 171, e 172 (flavum), pro compresso obducto. - ipertensione; maladie coronaire stabile - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

servier (suisse) sa - atorvastatinum, perindoprilum, amlodipinum - compressa rivestita con film - atorvastatinum 20 mg ut atorvastatinum calcicum trihydricum 21.64 mg, perindoprilum argininum 5 mg corresp. perindoprilum 3.395 mg, amlodipinum 5 mg ut amlodipini besilas 6.935 mg, calcii carbonas, lactosum monohydricum 54.92 mg, cellulosum microcristallinum, carboxymethylamylum natricum corresp. natrium 0.5 - 0.75 mg, hydroxypropylcellulosum, maltodextrinum, magnesii stearas, pellicule: glycerolum, hypromellosum, macrogolum 6000, magnesii stearas, e 171, e 172 (flavum), pro compresso obducto. - ipertensione; maladie coronaire stabile - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

servier (suisse) sa - atorvastatinum, perindoprilum, amlodipinum - compressa rivestita con film - atorvastatinum 20 mg ut atorvastatinum calcicum trihydricum 21.64 mg, perindoprilum argininum 10 mg corresp. perindoprilum 6.790 mg, amlodipinum 5 mg corresp. amlodipini besilas 6.935 mg, calcii carbonas, lactosum monohydricum 54.92 mg, cellulosum microcristallinum, carboxymethylamylum natricum corresp. natrium 0.5 - 0.75 mg, hydroxypropylcellulosum, maltodextrinum, magnesii stearas, pellicule: glycerolum, hypromellosum, macrogolum 6000, magnesii stearas, e 171, e 172 (flavum), pro compresso obducto. - ipertensione; maladie coronaire stabile - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

servier (suisse) sa - atorvastatinum, perindoprilum, amlodipinum - compressa rivestita con film - atorvastatinum 20 mg ut atorvastatinum calcicum trihydricum 21.64 mg, perindoprilum argininum 10 mg corresp. perindoprilum 6.790 mg, amlodipinum 10 mg ut amlodipini besilas 13.87 mg, calcii carbonas, lactosum monohydricum 54.92 mg, cellulosum microcristallinum, carboxymethylamylum natricum, natrium 0.5 - 0.75 mg, hydroxypropylcellulosum, maltodextrinum, magnesii stearas, pellicule: glycerolum, hypromellosum, macrogolum 6000, magnesii stearas, e 171, e 172 (flavum), pro compresso obducto. - ipertensione; maladie coronaire stabile - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

servier (suisse) sa - atorvastatinum, perindoprilum, amlodipinum - compressa rivestita con film - atorvastatinum 40 mg ut atorvastatinum calcicum trihydricum 43.28 mg, perindoprilum argininum 10 mg corresp. perindoprilum 6.790 mg, amlodipinum 10 mg ut amlodipini besilas 13.87 mg, calcii carbonas, lactosum monohydricum 109.84 mg, cellulosum microcristallinum, carboxymethylamylum natricum corresp. natrium 1 - 1.5 mg, hydroxypropylcellulosum, maltodextrinum, magnesii stearas, pellicule: glycerolum, hypromellosum, macrogolum 6000, magnesii stearas, e 171, e 172 (flavum), pro compresso obducto. - ipertensione; maladie coronaire stabile - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - carcinoma, polmone non a piccole cellule - agenti antineoplastici - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

les laboratoires servier - perindopril - perindopril